Abstract
Percutaneous coronary intervention (PCI) has survival and MI-prevention benefits in patients with acute coronary syndromes (ACS), and it reduces angina frequency and improves exercise tolerance in patients with stable coronary artery disease (CAD). Do the survival and MI-prevention benefits extend to stable CAD patients? In the COURAGE trial, 2287 patients (mean age, 62; 85% men; 33.5% with diabetes) were randomized to PCI plus optimal medical therapy or to optimal medical therapy alone. All patients had either …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
